Glycogen Storage Disease Type I (Von Gierke Disease)
A rare inherited disorder of glucose-6-phosphatase that causes severe fasting hypoglycemia, hepatomegaly, and metabolic complications from infancy.
- Autosomal Recessive
- Affects G6PC / SLC37A4 Genes
- Lifelong Dietary Management
- Most Common In
- Infants (presents 3-4 months)
- Inheritance
- Autosomal Recessive
- Key Gene
- G6PC (Ia) / SLC37A4 (Ib)
- Primary Management
- Dietary Therapy
Condition Overview
Glycogen Storage Disease Type I (GSD I), also known as Von Gierke disease, is a rare inherited metabolic disorder caused by deficiency of the glucose-6-phosphatase enzyme complex, which is required for the final step of glucose release from the liver during fasting. Without this enzyme, glycogen and glucose precursors accumulate in the liver and kidneys while blood glucose falls dangerously low between feeds.
GSD I is divided into Type Ia, caused by mutations in the G6PC gene, and Type Ib, caused by mutations in the glucose-6-phosphate transporter gene SLC37A4. Both subtypes cause similar metabolic disease, though Type Ib also carries a risk of neutropenia and inflammatory bowel-like disease.
Types and Subtypes
GSD I is classified based on which component of the glucose-6-phosphatase system is affected.
Symptoms and Signs
Symptoms typically appear around 3 to 4 months of age, when overnight feeding intervals lengthen.
Causes and Risk Factors
GSD I is caused by inherited mutations affecting the glucose-6-phosphatase complex.
Diagnosis and Investigations
Diagnosis combines clinical suspicion, metabolic testing, and confirmatory genetic analysis.
Disease Severity Classification
GSD I is not staged like cancer but is classified by metabolic control and organ involvement.
Standard Treatment
Treatment is centered on preventing hypoglycemia through continuous glucose supply.
Advanced & Emerging Therapies
Research is exploring options beyond dietary management.
Gene Therapy
AAV-Mediated G6PC Gene Replacement
Investigational gene therapy approaches aim to restore hepatic glucose-6-phosphatase activity and reduce dependence on strict dietary regimens.
mRNA Therapy
Investigational mRNA-Based Enzyme Restoration
Early-phase approaches exploring mRNA delivery to restore enzyme function are under investigation.
Transplantation
Liver Transplantation
Reserved for patients with multiple or malignant hepatic adenomas or uncontrollable metabolic instability.
Biomarkers & Monitoring Parameters
Several laboratory markers guide ongoing management of GSD I.
When to Seek a Second Opinion
A second opinion can be valuable at several points in the GSD I journey.
Clinical Trials & Research
Prognosis & Outcomes
With consistent dietary management, most individuals with GSD I can lead active lives, though lifelong monitoring is required.
Supportive Care
Comprehensive supportive care improves quality of life for individuals with GSD I.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by GSD Type I access specialist metabolic disease consultations, review genetic and metabolic reports, and explore eligibility for emerging gene therapy clinical trials.
Get a free case reviewFrequently Asked Questions
GSD Type I (Von Gierke disease) is a rare inherited metabolic disorder caused by deficiency of glucose-6-phosphatase, an enzyme needed to release glucose from the liver during fasting. This leads to severe low blood sugar, an enlarged liver, and other metabolic abnormalities.
It is caused by inherited mutations in the G6PC gene (Type Ia) or SLC37A4 gene (Type Ib), passed down in an autosomal recessive pattern.
Diagnosis involves fasting glucose and metabolic blood tests followed by confirmatory genetic testing of the G6PC or SLC37A4 genes.
Treatment centers on frequent feeding and uncooked cornstarch therapy to maintain stable blood glucose, along with dietary avoidance of fructose and galactose.
With consistent dietary management and regular specialist follow-up, many children grow and develop well, though lifelong monitoring for liver and kidney complications is needed.
Long-term complications can include hepatic adenomas, kidney disease, gout, and growth delay if metabolic control is suboptimal.
There is currently no cure, but gene therapy approaches are being studied in clinical trials as a potential future option to restore enzyme function.
Yes. CancerFax can review your medical reports and genetic test results, help coordinate second opinions with metabolic disease specialists, and assist in exploring enzyme replacement therapy, gene therapy trials, or transplant evaluation at centers in India, China, and internationally.